c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

Blasco, Rafael B., Francoz, Sarah, Santamaría, David, Cañamero, Marta, Dubus, Pierre, Charron, Jean, Baccarini, Manuela, Barbacid, Mariano·2011·Cancer Cell
DOI 10.1016/j.ccr.2011.04.002

Cited by (305)

Items 301–305 of 305

  1. BindingDB Entry 50007079: Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.
    BindingDB · 2021 · UC San Diego
  2. BindingDB Entry 50049294: Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
    BindingDB · 2019 · UC San Diego
  3. BindingDB Entry 50023484: Peptide inhibitors targeting Ras and Ras-associated protein-protein interactions.
    BindingDB · 2026 · UC San Diego
  4. BindingDB Entry 50046149: Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    BindingDB · 2016 · UC San Diego
  5. Lentiviral-Based Approach for the Validation of Cancer Therapeutic Targets in Vivo
    Chiara Ambrogio, Patrick Stern, Claudio Scuoppo, Harald D. Kranz, Mariano Barbacid, David Santamarı́a · 2014 · BioTechniques